Background Nogo-B (Reticulon 4B) accentuates hepatic fibrosis and cirrhosis, but the mechanism remains
Introduction
Liver fibrosis and its end-stage manifestation cirrhosis represent clinical challenges worldwide.
Hepatic stellate cell (HSC) activation is the cardinal feature that results in hepatic fibrosis. When stimulated by reactive oxygen species or cytokines in response to various hepatic insults, quiescent HSCs are transformed to myofibroblasts (MF-HSCs) that proliferate and secrete collagen. [1] [2] [3] [4] Studies have demonstrated that apoptosis of activated HSCs can reverse fibrosis. [5] [6] [7] [8] [9] [10] [11] [12] [13] Thus, the mechanisms that control MF-HSC apoptosis may represent potential therapeutic targets that result in fibrosis resolution. [14] [15] [16] Nogo-B, also known as Reticulon 4B, is a member of the reticulon protein family that are localized primarily to the endoplasmic reticulum (ER). 17, 18 Four groups of Reticulons, 1, 2, 3 and 4, exist with each having multiple isoforms. Reticulon 4 has three isoforms, Nogo-A, B and C. The most recognized isoform, Nogo-A (200 kDa), a potent neural outgrowth inhibitor, [19] [20] [21] is mainly expressed in the nervous system. [22] [23] [24] Nogo-C (25 kDa) is highly expressed in the differentiated muscle fibers and somewhat in the brain; 17, 18, 22 its function remains unclear.
Nogo-B (55 kDa), a splice variant of Nogo-A, is expressed in most tissues and has been reported for its role in modulating endothelial and smooth muscle cellular responses following injury in a variety of organs/tissues, including blood vessels, 25, 26 lung, 27, 28 kidney, 29 and liver. 30 We previously demonstrated that the absence of Nogo-B in a murine model blocks the progression of fibrosis/cirrhosis and the development of portal hypertension. 30 Further, we showed that lack of Nogo-B decreases the levels of α-smooth muscle actin (α-SMA), a marker of MF-HSCs, in murine cholestatic livers. These findings led us to hypothesize that absence of Nogo-B may increase the susceptibility of MF-HSCs to apoptosis thereby reducing fibrosis/cirrhosis in mice. In this study, we investigated the role of Nogo-B in MF-HSC apoptosis in vivo and in vitro.
Materials and Methods

Animals
All animal studies were approved by the Institutional Animal Care and Use Committees of Yale University and Veterans Affairs Connecticut Healthcare System. Studies were performed in adherence with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Nogo-A/B knockout (NGB KO) mice were a gift from Stephen Strittmatter 31 and Mark Tessier-Lavigne.
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Induction of hepatic fibrosis and cirrhosis
Five male NGB KO and their littermate wild-type (WT) mice at the age of 1 month were exposed to carbon tetrachloride (CCl 4 ) by inhalation for 12 weeks. 33, 34 Phenobarbital (0.35 g/L) was added to the drinking water 3 days prior to CCl 4 exposure to accentuate fibrosis/cirrhosis. Mice were placed in a gas chamber (60 x 40
x 20 cm) under a fume hood and exposed to CCl 4 gas three times a week. The duration of CCl 4 inhalation was 1-2 minutes for the first 3 weeks and was increased to 3-5 minutes thereafter. CCl 4 exposure was stopped 5-7 days before the experiment. Phenobarbital was no longer added to the drinking water at the time CCl 4 exposure was stopped. Age-matched untreated WT and NGB KO mice were used as treatment controls. Liver samples were isolated and fixed in formalin. Paraffin-embedded liver samples were prepared for histological analyses.
Sirius red staining
Histological specimens were embedded in paraffin and cut to 6μm-thick sections. Sections were deparaffinized by three-time washes of xylene for 5 minutes each, and rehydrated with 100%, 90% and 70% ethanol for 5minutes each. After rinsing in distilled water for 5 minutes, sections were incubated in 0.1% Sirius red solution (Sigma-Aldrich, St. Louis, MO) for 90 minutes, soaked in 0.5% acetic acid buffer, and dehydrated gradually with 70%, 90% and 100% ethanol and 3 times with xylene for 5 minutes. Fibrosis was determined by calculating the percent Sirius red-positive area (i.e., collagen-positive area) over the total area analyzed. Image J1.43u
(Wayne Rasband, National Institutes of Health, Bethesda, MD) was used for image analysis of the entire liver sections.
At least 20 images per liver section were randomly taken and used for the analyses.
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Immunohistochemistry
Paraffin-embedded sections (6μm-thick) were deparaffinized and rehydrated as described above.
Antigen retrieval was performed by placing sections in 10mM sodium citrate buffer pH 6.0, heated in a microwave, placed in a steamer for 30 minutes, and steadily cooled down on the bench top for 20 minutes. Sections were then treated with 3% hydrogen peroxidase diluted with methanol, followed by blocking with 5% Donkey serum plus 1% bovine serum albumin (BSA) in PBS. After blocking non-specific biotin and avidin using a kit 
Isolation of hepatic stellate cells (HSCs)
Primary HSCs were isolated from WT and NGB KO mice by in situ perfusion of livers with pronase-collagenase, followed by density gradient centrifugation using Nycodenz (Histodenz; Sigma-Aldrich) density gradients as described. 35, 36 HSCs were cultured in Dulbecco's Modified Eagle's Medium with high glucose (DMEM; GIBCO, Invitrogen) supplemented with 10% fetal bovine serum (FBS), antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin) and 1% L-glutamine in humidified air containing 5% CO 2 at 37 o C.
HSCs were cultured for more than 14 days to fully transform to myofibroblasts (MF-HSCs). 
Hepatocyte isolation
Hepatocytes were isolated from WT and Nogo-B KO mice by collagenase perfusion as previously (1:1,000; Cell Signaling), rabbit anti-cleaved caspase-3 (1:1,000; Cell Signaling), rabbit anti-cleaved caspase-8
(1:1,000; Cell Signaling), rabbit anti-Bcl-xL (1:1,000; Cell Signaling), mouse anti-caspase-9 (1:1,000; Cell Signaling), or mouse anti-β actin (1:5,000; Sigma-Aldrich). After washing three times with TBST for 10 minutes, membranes were incubated with fluorophore-conjugated secondary antibodies (either 680nm or 800nm emission).
Detection and quantification of bands were performed using the Odyssey Infrared Imaging System (Li-Cor Biotechnology, Lincoln, NE). Hsp90 and β-actin were used for loading controls.
TUNEL and Annexin V staining
MF-HSCs were fixed with 4% paraformaldehyde (PFA) in PBS for 1 hour at room temperature, followed by washing with PBS three times for 5 minutes each. MF-HSCs were then incubated with a permeabilization buffer containing 0.1% Triton X-100 in 0.1% sodium citrate on ice for 5 minutes. TUNEL staining was performed using a commercial kit (In Situ Cell Death Detection Kit; Roche Diagnostics) by incubating MF-HSCs for 1 hour at room temperature. Recombinant DNase I (Roche Diagnostics) 3 U/mL was incubated for 10 minutes as a positive control prior to labeling procedures. The label solution conjugated with fluorescein alone was used as a negative control. After washing three times with PBS for 5 minutes each, MF-HSCs were mounted with a mounting media containing DAPI (Invitrogen). Annexin V staining was performed using Alexa Fluor 488-conjugated Annexin V/Dead Cell Apoptosis Kit (Molecular Probes; Invitrogen).
Images were taken using a fluorescent microscope (Eclipse E800; Nikon) and recorded with Openlab3 software (PerkinElmer).
Nogo-B knockdown in human hepatic stellate cell line (LX2)
LX-2 cells were a kind gift from Dr. Scott L. Friedman (Mount Sinai School of Medicine, NY). 
Nogo-B overexpression in LX2
LX2 cells were seeded in 12-well tissue culture plates at a density of 1.0 x 10 5 cells/well and incubated in humidified air containing 5% CO 2 at 37 o C for overnight. Cells were transfected with 0.5 μg of HA-tagged Nogo-B plasmid (or pcDNA3 vector alone as a negative control) in 500 μL OptiMEM (GIBCO, Invitrogen) with 1.5 μl FuGENE 6 (Roche Diagnostics) and incubated for 6 hours. Then, 500 μL of DMEM containing 10% FBS and 1% L-glutamine was added to each well. After 48 hours of incubation, cells were starved in DMEM without FBS for 24 hours, followed by the treatment with 100nM STS for 4 and 8 hours.
For immunocytochemistry, cells were washed with cold PBS and fixed with 4% PFA in PBS for 20 minutes at room temperature. After washing three times with PBS for 5 minutes each, cells were incubated in a buffer containing 0.3% Triton X-100, 5% donkey serum and 1% BSA in PBS at room temperature for 1 hour.
After washing with PBS, cells were incubated with antibodies including rat anti-HA (1:1,000; Roche Diagnostics) and rabbit anti-cleaved caspase-3 (1:1,000; Cell Signaling), which were diluted with 1% BSA in PBS at 4 o C for overnight. Cells were then incubated with Alexa Fluor 488 donkey anti-rat IgG (1:500; Invitrogen) or Alexa
Fluor 588 donkey anti-Rabbit IgG (1:500; Invitrogen) as a secondary antibody for 1 hour at room temperature.
Cells were mounted with a DAPI containing media (Invitrogen). Images were taken by a fluorescent microscope (Eclipse E800; Nikon) and recorded using Openlab3 software (PerkinElmer).
Statistical analysis
Data were expressed as mean + standard error (SE). Statistical differences among the mean values of multiple groups were determined using analysis of variance (ANOVA) followed by a Student t test. Values of p < 0.05 were considered statistically significant.
Results
Lack of Nogo-B reduces fibrosis and facilitates apoptosis in fibrotic areas of the mouse cirrhotic liver.
Sirius red staining was performed in cirrhotic livers isolated from WT and NGB KO mice that underwent CCl 4 inhalation for 12 weeks ( Figure 1A left panel) . Liver fibrosis was significantly reduced in NGB KO livers compared with WT livers ( Figure 1A left and right panels, p = 0.012). This is similar to the results observed using a murine model of bile duct ligation (BDL). 30 Apoptotic cells, as indicated by cleaved caspase-3
immunolabeling, were seen in fibrotic regions of Nogo-B KO livers, whereas they were much less apparent in WT livers ( Figure 1B) . NGB KO cirrhotic livers demonstrated co-localization of TUNEL staining with α-SMA positive cells, while TUNEL staining was not apparent in WT cirrhotic livers ( Figure 1C ). These results suggest that the lack of Nogo-B reduces fibrosis and enhances apoptosis of activated HSCs in experimental cirrhosis.
Lack of Nogo-B facilitates apoptosis of myofibroblasts derived from hepatic stellate cells (MF-HSCs).
Nogo-B's role in apoptosis of MF-HSCs was examined using staurosporine (STS), an inducer of apoptosis. [40] [41] [42] WT and NGB KO MF-HSCs were treated with 1μM STS for 16 hours and examined for TUNEL and Annexin V labeling. NGB KO MF-HSCs showed significantly higher percentages of TUNEL and Annexin V positive nuclei compared with WT MF-HSCs (Figures 2A and B , p < 0.01).
We also determined the levels of several apoptotic markers in WT and NGB KO MF-HSCs after treatment with 1μM STS for 0, 2, 4, 6, 8 and 10 hours (Figure 3) . Levels of cleaved PARP were increased in a time-dependent manner in both WT and NGB KO MF-HSCs, but were significantly higher in NGB KO MF-HSCs 4, 6 and 10 hours after STS treatment (p < 0.05 for 4 and 6 hours and p < 0.01 for 10 hours, Figure 3B top panel).
Similarly, cleaved caspase-3 levels were significantly increased in NGB KO MF-HSCs 4, 6 and 8 hours after STS treatment (p < 0.05 for 4 and 6 hours and p < 0.01 for 8 hours, Figure 3B middle panel). The levels of cleaved caspase-8 were also significantly increased in NGB KO MF-HSC 4, 6 and 8 hours after STS treatment (p < 0.05, Figure 3B bottom left panel). Cleaved caspase-9 and Bcl-xL levels did not differ between these two groups at all time points examined ( Figure 3B bottom middle and right panels). This may reflect the fact that Bcl-xL primarily acts on mitochondria and prevents apoptosis by inhibiting the activity of caspase-9. 43, 44 These results indicate that the lack of Nogo-B facilitates apoptosis of MF-HSCs in response to STS.
Lack of Nogo-B does not influence hepatocyte apoptosis in response to staurosporine (STS).
To investigate the possibility that Nogo-B may modulate apoptosis in hepatocytes, hepatocytes from WT and NGB KO mice were treated with STS ( Figure 4 ). Hepatocytes required a higher dose of STS than MF-HSCs to induce apoptosis (10 vs. 1 μM, respectively). Moreover, there was no difference in the levels of apoptotic markers between WT and NGB KO hepatocytes. These results indicate that the absence of NGB preferentially sensitize MF-HSCs rather than hepatocytes to apoptosis under conditions of experimental cirrhosis.
Knockdown of Nogo-B increases apoptosis in human hepatic stellate cells (LX2).
To confirm Nogo-B's role in apoptosis in human MF-HSCs, LX2 cells were transfected with Nogo-B siRNA to suppress Nogo-B expression. We then tested apoptosis in those cells, treated with100nM STS for 0, 2, 
Overexpression of Nogo-B blocks apoptosis in human hepatic stellate cells (LX2).
To 
Nogo-B is involved in ER stress-induced apoptosis in myofibroblasts derived from hepatic stellate cells (MF-HSCs).
In 
Discussion
Experimental studies have demonstrated that inducing HSC apoptosis may reverse hepatic fibrosis. [45] [46] [47] [48] [49] In this study, we have discovered that lack of Nogo-B reduces liver fibrosis and enhances apoptosis of myofibroblasts derived from HSCs (MF-HSCs, i.e., activated HSCs) in mice that underwent carbon tetrachloride We previously reported that Nogo-B levels are elevated in fibrotic areas of human cirrhotic liver specimens as well as in mouse cholestatic models of fibrosis after bile duct ligation. Nogo-B gene deletion blocks the progression of liver cirrhosis and portal hypertension, suggesting that Nogo-B promotes liver fibrosis.
This anti-fibrotic effect was mediated through TGFβ/Smad2 signaling in myofibroblasts. 30 The current study adds to these earlier findings by showing that Nogo-B represents an anti-apoptotic factor for HSCs in the setting of experimental cirrhosis. Moreover, this study confirms that Nogo-B facilitates fibrosis in the CCl 4 model of cirrhosis and supports our earlier studies that demonstrate a pro-fibrotic role for Nogo-B in the liver. Previous work using Nogo-B KO mice in a kidney injury model observed no significant differences in tissue fibrosis. 29 The length of injury and the different organ systems studied may account for these different outcomes.
We have also examined pathways through which Nogo-B carries out anti-apoptosis of MF-HSCs with a focus on ER stress, Fas ligand, and mitochondrial pathways. Since ER stress induces apoptosis in HSCs 12 and
Nogo-B regulates ER structure, 17, 18, 28, 50 we hypothesized that Nogo-B's anti-apoptotic effect on MF-HSCs might be mediated by ER stress. In fact, treatment with tunicamycin significantly increased the levels of cleaved caspase-3 and -8 in Nogo-B KO MF-HSCs, compared with their WT counterparts. These indicate that Nogo-B's anti-apoptotic role in MF-HSCs is due, at least in part, to its involvement in ER stress ( Figure 7C ). Thus,
Nogo-B appears to increase the susceptibility of MF-HSCs to ER stress thereby predisposing to apoptosis.
In contrast, our study indicates that Nogo-B's anti-apoptotic role in MF-HSCs is not likely via the mitochondrial pathway, since the level of Bcl-xL, an indicator of mitochondria-mediated apoptosis, did not differ between WT and Nogo-B KO MF-HSCs in response to staurosporine. Although we found significantly higher levels of cleaved caspase-8 in Nogo-B KO MF-HSCs in response to staurosporine, caspase-8 is known to be activated through the ER stress pathway 51 and/or the death receptor pathway. [52] [53] [54] In addition, treatment with hypertension. 28 Overall, Nogo-B may function as a pro-apoptotic or anti-apoptotic protein, depending on the specific cell type.
Apoptosis can also mediate pro-fibrotic responses in the liver depending on the cell type involved.
Hepatocyte apoptosis is thought to facilitate fibrosis by triggering and maintaining HSC activation in response to hepatic insults. 58 To address this issue, we examined whether the levels of apoptotic markers (cleaved PARP, cleaved caspase-3 and-8, and Bcl-xL) in cultured WT and Nogo-B KO hepatocytes differed in response to staurosporine. No differences in apoptotic activity were observed, indicating that Nogo-B's anti-apoptotic effect is specific to MF-HSCs.
In conclusion, absence of Nogo-B specifically increases apoptotic responses of MF-HSCs, which is associated with a reduction in hepatic fibrosis. Therefore, Nogo-B may be a potential target for the treatment of liver fibrosis/cirrhosis. hours. Western blot analysis for apoptotic markers, including cleaved PARP, cleaved caspase-3 and -9, and Bcl-xL, was performed. β-actin was used as a loading control. 
